Seagen Inc – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

13 Seagen Inc Expert Interviews, now on BamSEC.

Powered by Tegus.

Financials Filter

ended 09/30/23 Q3

ended 06/30/23 Q2

ended 03/31/23 Q1

ended 12/31/22 FY 2022

ended 09/30/22 Q3

Prospectuses and Registrations Filter

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Baker Julian, Baker Felix, Baker Bros. Advisors LP, Baker Brothers Life Sciences LP, 667, L.P., Baker Bros. Advisors (GP) LLC

Baker Bros. Advisors LP

Simonian Nancy A

News Filter

Completion of Acquisition or Disposition of Assets, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Material Modification to Rights of Security Holders, Change of Control, Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Financial Statements or Exhibits

Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

PADCEV® (Enfortumab Vedotin-Ejfv) and KEYTRUDA® (Pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Proxy related to merger

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Confidential treatment order

SEC STAFF LETTER

SEC STAFF LETTER

Confidential treatment order